Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment (HI)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Movetis
ClinicalTrials.gov Identifier:
NCT01134185
First received: May 21, 2010
Last updated: April 17, 2012
Last verified: October 2011

May 21, 2010
April 17, 2012
May 2010
February 2011   (final data collection date for primary outcome measure)
Pharmacokinetics [ Time Frame: 6 days ] [ Designated as safety issue: No ]
Evaluation of prucalopride in blood immediately before and at 17 timepoints post dosing and in urine at 8 collection time points.
Same as current
Complete list of historical versions of study NCT01134185 on ClinicalTrials.gov Archive Site
Safety and tolerability [ Time Frame: 6 days ] [ Designated as safety issue: No ]
Evaluation of safety parameters by measuring adverse events, safety, blood and urine samples, ECGs, vital signs and physical examinations.
Same as current
Not Provided
Not Provided
 
Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment
Evaluation of Pharmacokinetics, Safety and Tolerability of a Single Dose of Prucalopride, in Subjects With Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects

This is a single centre, open-label phase I trial to investigate the effects of moderate to severe hepatic impairment on the pharmacokinetics of prucalopride in comparison with healthy volunteers. Furthermore the short-term safety and tolerability of a single dose of prucalopride will be assessed.

In this phase I trial two groups of 6 to 8 hepatically impaired subjects will be evaluated. The first group are the moderate hepatic impairment (Grade B) subjects and the second group the severe hepatic impairment (grade C) subjects. Subjects for both groups will be recruited and treated in parallel. After all subjects with hepatic impairment completed the treatment a third group with matching healthy volunteers will be recruited. Eight healthy subjects will be selected matching for age, gender and weight (BMI based).

The subjects will receive a single dose of 2 mg prucalopride in the morning after overnight fasting followed by the consumption of a standard breakfast after 2 hours.

Pharmacokinetic evaluation of blood samples will be done immediately before and at a specific timepoint up to 120h post-dosing. Urine samples will be taken to determine prucalopride.

Adverse events, including serious adverse events, will be reported from signing the Informed Consent until the last visit. Safety blood samples and a urine sample for urinalysis will be taken.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatic Impairment
  • Drug: prucalopride
    single oral dose of 2 mg prucalopride
  • Drug: prucalopride
    single dose of 2 mg prucalopride
  • Active Comparator: Group I
    Moderate hepatic impairment (grade B)
    Intervention: Drug: prucalopride
  • Active Comparator: Group II
    Severe hepatic impairment (grade C)
    Intervention: Drug: prucalopride
  • Active Comparator: Group III
    healthy subjects
    Intervention: Drug: prucalopride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
February 2011
February 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Main inclusion criteria for hepatic impairment subjects:

    • Moderate (Grade B) or severe (Grade C) chronic hepatic impairment according to Child-Pugh classification; Hepatic impairment must be stable, both clinically and biochemically;
    • Within the normal range of body height and weight on the basis of the Body Mass Index.
  • Main inclusion criteria for healthy subjects:

    • Matching on sex, age and weight(BMI based).

Exclusion Criteria:

  • History or suspicion of barbiturate, amphetamine or narcotic abuse; Suspicion of current alcohol abuse;
  • Clinical suspicion or laboratory evidence of unstable hepatic impairment or acute liver injury;
  • Clinically relevant renal disease as judged by the investigator.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT01134185
M0001-C103
No
Movetis
Movetis
Not Provided
Not Provided
Movetis
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP